https://scholars.lib.ntu.edu.tw/handle/123456789/588461
標題: | Pentoxifylline Decreases Dialysis Risk in Patients with Advanced Chronic Kidney Disease | 作者: | Wu P.-C. Wu C.-J. Lin C.-J. Pan C.-F. Chen C.-Y. TAO-MIN HUANG Wu C.-H. SHUEI-LIONG LIN YUNG-MING CHEN Chen L. VIN-CENT WU NSARF Group, Kidney Consortium |
公開日期: | 2015 | 出版社: | Nature Publishing Group | 卷: | 98 | 期: | 4 | 起(迄)頁: | 442-449 | 來源出版物: | Clinical Pharmacology and Therapeutics | 摘要: | Few studies evaluated the effects of pentoxifylline on hard endpoints in patients with predialysis stage 5 chronic kidney disease (CKD). Thus, we tried to explore the effects of pentoxifylline and its interaction with renin-angiotensin-aldosterone system (RAAS) blockade on the development of endstage renal disease (ESRD) andmortality. This nationwide cohort study retrospectively included patients who had a serum creatinine level of > 6mg/dL and received erythropoiesis-stimulating agents (ESAs) between 2000 and 2010.We analyzed 7,366 pentoxifylline users and 7,366 propensity score-matched nonusers. Using Cox proportional hazardmodels, pentoxifylline reduced the risks of ESRD and the composite renal outcome but not that of mortality. In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitormonotherapy. This study suggests pentoxifylline is efficacious in slowing progression to ESRD in patients with predialysis stage 5 CKD. ? 2015 American Society for Clinical Pharmacology and Therapeutics. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84952759707&doi=10.1002%2fcpt.173&partnerID=40&md5=aa31fe14ab3f86d54bb6a018af89a9c4 https://scholars.lib.ntu.edu.tw/handle/123456789/588461 |
ISSN: | 0009-9236 | DOI: | 10.1002/cpt.173 | SDG/關鍵字: | angiotensin receptor antagonist; creatinine; dipeptidyl carboxypeptidase inhibitor; pentoxifylline; angiotensin 1 receptor antagonist; biological marker; creatinine; dipeptidyl carboxypeptidase inhibitor; pentoxifylline; urinary tract agent; adult; Article; chronic kidney disease; cohort analysis; controlled study; creatinine blood level; dialysis; disease course; end stage renal disease; female; follow up; human; long term survival; major clinical study; male; monotherapy; mortality; prescription; priority journal; renal protection; renin angiotensin aldosterone system; retrospective study; risk reduction; aged; blood; chi square distribution; comparative study; drug combination; drug effects; Kidney Failure, Chronic; middle aged; multivariate analysis; pathophysiology; propensity score; proportional hazards model; Renal Insufficiency, Chronic; renal replacement therapy; risk factor; statistical model; time; treatment outcome; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Chi-Square Distribution; Creatinine; Disease Progression; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pentoxifylline; Propensity Score; Proportional Hazards Models; Renal Dialysis; Renal Insufficiency, Chronic; Renin-Angiotensin System; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Urological Agents |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。